Preexposure Prophylaxis in HIV Serodiscordant Couples

Partners PrEP Trial
**Oral PrEP for Heterosexual Couples in Kenya and Uganda**

**Partners PrEP: Study Design**

**Background:** Randomized, placebo-controlled trial that examined efficacy and safety of tenofovir DF and tenofovir DF-emtricitabine as preexposure prophylaxis in heterosexual HIV-1 serodiscordant couples from Kenya and Uganda.

**Inclusion Criteria** (4758 enrolled)
- 18 years of age or older
- HIV-1-serodiscordant couples
- HIV-seropositive partner: not receiving ART and Did not meet Kenyan or Ugandan guidelines for initiation of ART
- HIV-seronegative partners: normal renal function; not infected with HBV; not breastfeeding

**Treatment Arms:**
- Placebo: 1 pill daily
- Tenofovir DF: 1 pill daily
- Tenofovir DF-emtricitabine: 1 pill daily

---

Oral PrEP for Heterosexual Couples in Kenya and Uganda

Partners PrEP: Study Design

4,758 Heterosexual, HIV-1-Serodiscordant Couples

- Placebo (n = 1584)
- Tenofovir DF (n = 1584)
- Tenofovir DF-Emtricitabine (n = 1579)

n = 1808
n = 2950

11 total couples found to be ineligible and not included in the intention-to-treat analysis.

Oral PrEP for Heterosexual Couples in Kenya and Uganda
Partners PrEP: Results

Study stopped July 2011 by DSMB because of PrEP efficacy

Conclusions: “Oral tenofovir DF and tenofovir DF-emtricitabine both protect against HIV-1 infection in heterosexual men and women.”

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.